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ABSTRACT
Objectives Circulating myeloid precursors are 
responsible for post- natal osteoclast (OC) differentiation 
and skeletal health, although the exact human precursors 
have not been defined. Enhanced osteoclastogenesis 
contributes to joint destruction in rheumatoid arthritis 
(RA) and tumour necrosis factor (TNF) is a well- known 
pro- osteoclastogenic factor. Herein, we investigated the 
interplay between receptor activator of nuclear factor 
kappa-Β ligand (RANK- L), indispensable for fusion of 
myeloid precursors and the normal development of OCs, 
and TNF in directing the differentiation of diverse pre- OC 
populations derived from human peripheral blood.
Methods Flow cytometric cell sorting and analysis was 
used to assess the potential of myeloid populations to 
differentiate into OCs. Transcriptomic, epigenetic analysis, 
receptor expression and inhibitor experiments were used 
to unravel RANK- L and TNF signalling hierarchy.
Results TNF can act as a critical homoeostatic regulator 
of CD14+ monocyte (MO) differentiation into OCs by 
inhibiting osteoclastogenesis to favour macrophage 
development. In contrast, a distinct previously 
unidentified CD14−CD16−CD11c+ myeloid pre- OC 
population was exempt from this negative regulation. In 
healthy CD14+ MOs, TNF drove epigenetic modification 
of the RANK promoter via a TNFR1- IKKβ-dependent 
pathway and halted osteoclastogenesis. In a subset 
of patients with RA, CD14+ MOs exhibited an altered 
epigenetic state that resulted in dysregulated TNF- 
mediated OC homoeostasis.
Conclusions These findings fundamentally re- 
define the relationship between RANK- L and TNF. 
Moreover, they have identified a novel pool of human 
circulating non- MO OC precursors that unlike MOs are 
epigenetically preconditioned to ignore TNF- mediated 
signalling. In RA, this epigenetic preconditioning occurs 
in the MO compartment providing a pathological 
consequence of failure of this pathway.
INTRODUCTION
Osteoclasts (OCs) are polykarion bone- resorbing 
cells that can be derived from either yolk sac 
erythro- myeloid progenitors or bone marrow/
circulating monocyte (MO) precursors1 supported 
by the receptor activator of nuclear factor kappa-Β 
(RANK) receptor and tumour necrosis factor 
(TNF) family cytokine RANK- ligand (RANK- L).2 3 
Circulating MO also have the capacity to differ-
entiate into macrophages (Mϕ) or dendritic cells 
(DCs).4 5 Recently, human ontogenetic and tran-
scriptomic studies have re- classified DCs, MO, 
MO- derived cells and tissue resident Mϕ based on 
their differentiation from specific precursor cells.6 7 
While murine studies have identified specific OC 
myeloid precursors8 that play a crucial role in post- 
natal OC differentiation in vivo,1, it is unclear 
whether specific non- MO circulating OC precur-
sors exist in humans. Moreover, how such precur-
sors respond to competing differentiating and 
activating cytokine signals and select their eventual 
cell fate is poorly understood.
Murine studies have shown that in combination 
with RANK- L, TNF is a direct maturation/acti-
vation stimulus of OC precursors.9–11 It has been 
assumed that TNF mediates equivalent actions 
across human OC precursors. Consistent with 
this notion, TNF is one of the main mediators of 
joint inflammation in inflammatory diseases such 
Key message
What is already known about this subject?
 ► OC differentiation and maturation from myeloid 
precursors relies on receptor activator of nuclear 
factor kappa-Β (RANK) signalling and murine 
studies suggest that tumour necrosis factor 
(TNF) is a potent coactivator.
 ► One of the gold standard therapy for 
rheumatoid arthritis includes blocking TNF 
although a consistent portion of patients do 
not respond and display progressive joint 
destruction.
What does this study add?
 ► We have discovered a novel non- monocyte 
(MO) osteoclast (OC) precursor population in 
the human peripheral blood and demonstrated 
its epigenetic and transcriptomic imprint 
towards OC differentiation.
 ► We have demonstrated that TNF can act as a 
homoeostatic regulator of classical peripheral 
CD14+ MOs by inhibiting their differentiation 
into OCs to favour macrophages and showed 
how this mechanism is epigenetically 
perturbated in a portion of patients with 
rheumatoid arthritis (RA) with active disease.
How might this impact on clinical practice or 
future developments?
 ► These data provide an important insight into 
the cellular and epigenetic heterogeneity in 
RA and can be used to develop alternative 
therapeutics for those patients that do not 
respond to current therapies.
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as rheumatoid arthritis (RA), which is associated with articular 
damage and systemic bone loss.12 13 Furthermore, in the clinical 
setting, treatment with TNF inhibitors has been shown to reduce 
articular erosion.14 However, the precise effects of TNF acting 
directly on human myeloid/MO/OC precursors remains ill- 
defined. Inflamed tissues, both in acute or chronic states, exhibit 
elevated levels of TNF, usually associated with MO recruitment 
and maturation even in the presence of RANK- L.15 It is unclear 
why in environments that are favourable to osteoclastogenesis, 
a preponderance of infiltrating myeloid precursors does not 
differentiate down the OC lineage.
Herein, we report the existence of a human CD14−C-
D16−CD11c+ myeloid precursor population that is epigeneti-
cally predisposed to rapidly differentiate into OCs. Notably, 
this population is unresponsive to a previously unrecognised 
homoeostatic TNF- mediated signal that fundamentally governs 
cell fate decisions in CD14+ MOs that favours Mϕ development. 
Moreover, we provide evidence that this effect is mediated by 
TNF via epigenetic regulation of the RANK promoter in circu-
lating CD14+ MOs and that this pathway is perturbed in RA.
MATERIALS AND METHODS
Detailed experimental procedures and analyses are provided in 
online supplemental files.
RESULTS
Distinct epigenetically primed OC precursors in human blood
Circulating CD14+ MOs are regarded as classical OC precur-
sors,16 but the existence of a distinct circulating human precursor 
is not known. To investigate the osteoclastogenic potential of 
circulating human myeloid cells we used fluorescence- activated 
cell sorting (figure 1A) to purify circulating MO subsets (classical 
Lin−HLA−DR+CD14+CD16−, intermediate Lin−HLA−DR+C-
D14+CD16+ and non- classical Lin−HLA−DR+CD14dimCD16++) 
and other myeloid cells (Lin−HLA−DR+CD14−CD16−). Culture 
of these populations with macrophage- colony stimulating factor 
(M- CSF) and RANK- L verified that classical MOs differen-
tiate into mature OCs while intermediate and non- classical 
populations only produced few and variable numbers of small 
OCs17 (figure 1B,C). Intriguingly, purified Lin−HLA−DR+C-
D14−CD16− myeloid cells differentiated into OCs, with 
numbers comparable to classical CD14+ MOs (figure 1B,C). 
Lin−HLA−DR+CD14−CD16− myeloid cells can be subdivided 
via CD11c expression into populations that contain conven-
tional pre- DCs (CD14−CD16−CD11c+) and plasmacytoid DCs 
(CD14−CD16−CD11c−)7; only the CD14−CD16−CD11c+ 
population was able to adhere and differentiate into mature OCs 
(figure 1D).
The in vivo kinetics of osteoclastogenesis from precursors to 
a mature OC are not clear in humans, however, murine studies 
have shown that preconditioned cells can mature into OCs 
within 48 hours.18 The in vitro generation of a mature OCs from 
circulating CD14+ MOs or in vitro differentiated MO- derived 
pre/immature DCs or Mϕ takes in excess of 7–14 days.5 19 20 We 
hypothesised that this reflects the non- preconditioned state of 
the precursor and thus time is required for in vitro cell differ-
entiation/trans- differentiation. In support of this, CD14+ MOs 
are preincubated overnight with M- CSF to generate CD14+ 
pre- OCs. This preincubation leads to upregulation of RANK 
and CSF1R (M- CSF receptor) transcripts (figure 1E),21 and 
increased tri- methylation of histone H3 at lysine 4 (H3K4me3) 
in the RANK promoter (figure 1E), indicative of a transcrip-
tionally active epigenetic state.22 In comparison, immediate 
ex vivo evaluation of the identified CD14−CD16−CD11c+ 
myeloid population revealed that they have higher levels of 
RANK transcript and decreased levels of CSF1R compared with 
classical CD14+ MOs (figure 1F). This was associated with an 
increased level of H3K4me3 at the RANK promoter but less at 
the CSF1R promoter of CD14−CD16−CD11c+ myeloid popu-
lation compared with donor- matched CD14+ MOs (figure 1F). 
Pre- OCs from both CD14+ MOs and CD14−CD16−CD11c+ 
cells were generated by M- CSF overnight incubation. Assess-
ment of OC differentiation 72 hours post- RANK- L stimulation, 
revealed that while CD14+ pre- OCs produce few small OCs 
at this time point, CD11c+ pre- OCs rapidly differentiate into 
macroscopically larger OCs, with numbers significantly higher 
than those differentiated from donor- matched CD14+ pre- OCs 
(figure 1G). Taken together, these results suggest that the circu-
lating CD14−CD16−CD11c+ myeloid population contains OC 
precursors that are in an epigenetically precommitted state to 
rapidly differentiate into mature OCs.
TNF over-rides RANKL-driven osteoclastogenesis of CD14+ 
circulating precursors but not CD14−CD16−CD11c+ precursors
TNF is a well- known pro- osteoclastogenic factor, both in 
vitro9 10 23 and in vivo.24–26 However, nothing is known about 
how human circulating precursors respond to simultaneous expo-
sure to TNF family member cytokines, as would be expected in 
a physiological setting. Therefore, we simultaneously stimulated 
human CD14+ pre- OCs and CD11c+ pre- OCs with RANK- L 
and TNF. Unexpectedly, we found that synchronised stimulation 
of CD14+ pre- OCs with RANK- L and TNF resulted in substan-
tial inhibition of osteoclastogenesis (figure 2A,B). The resulting 
cells exhibited Mϕ morphology, although dissimilar to either 
regulatory M- CSF- driven Mϕ (M- Mϕ) or pro- inflammatory 
GM- CSF- driven Mϕ (GM- Mϕ) (online supplemental figure S1).
In comparison to what was observed in CD14+ pre- OCs, TNF 
was unable to inhibit the generation of mature OCs derived from 
CD11c+ pre- OCs (figure 2A,B). Extending the duration of differ-
entiation to 14 days, we found that TNF completely abrogated 
the resorptive activity of CD14+ pre- OCs but had no effect on 
CD11c+ pre- OCs resorption (figure 2C,D). In order to demon-
strate that CD11c+ pre- OCs were not completely unrespon-
sive to TNF, the secretion of relevant cytokines was evaluated. 
Notably, TNF stimulation resulted in the increased secretion 
of interferon-γ in CD11c+ pre- OCs but not CD14+ pre- OCs 
(online supplemental figure S2). Conversely, TNF stimulation 
resulted in the secretion of interleukin (IL)-12, IL-1β and IL-6 in 
CD14+ pre- OCs but not CD11c+ pre- OCs (online supplemental 
figure S2). Thus, circulating CD14−CD16−CD11c+ precur-
sors and CD14+ MOs display a fundamental difference in their 
response to TNF, with CD14−CD16−CD11c+ precursors able to 
differentiate into mature and functional OCs.
TNF-mediated epigenetic modification of the RANK promoter 
controls RANK transcription and expression in CD14+-derived 
OC precursors
To further explore the unexpected inhibition of osteoclastogen-
esis by TNF, we extended our cellular and molecular character-
isation of CD14+ pre- OCs. Increasing RANK- L concentration 
to potentially outcompete the simultaneous TNF signal did not 
restore OC differentiation (figure 3A). In comparison, there was 
a TNF dose- dependent reduction in the development of mature 
multinucleated OCs (figure 3B). To demonstrate TNF specificity 
and exclude the possibility of cross- contamination, addition 
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Figure 1 Identification and epigenetic state of osteoclast (OC) precursor populations in human blood. (A–D) Sorted peripheral blood mononuclear 
cells (PBMCs) were plated overnight with 25 ng/mL macrophage- colony stimulating factor (M- CSF) and subsequently 25 ng/mL receptor activator of 
nuclear factorkappa- B ligand (RANK- L) was added to differentiate cells into OCs. At day 7 cells were fixed and stained for TRAP. (A) Representative 
flow cytometric plots showing the gating strategy used to sort monocyte (MO) subsets and CD14−CD16−CD11c+ myeloid cells. Cells were pre- 
gated as single Lin− (CD19−CD3−CD15−CD56−) HLA- DR+. Numbers indicate percentage of parental subset. (B) Representative digital reconstructed 
wells at 4× (with a boxed 10× magnification) and (C) quantification of multinucleated (nuclei ≥3) cells (MNCs) TRAP+ (purple) OC differentiated 
from CD14dimCD16++, CD14+CD16+, CD14+CD16− and CD14−CD16− subsets. (D) Representative digital images of TRAP stained wells at 4× with 
boxed 10× magnification images of CD14−CD16−CD11c− and CD14−CD16−CD11c+ cells. (E–G) CD14+ MOs and CD14−CD16−CD11c+ precursors 
were magnetically enriched from PBMCs (purity ≥96%) and incubated overnight with 25 ng/mL M- CSF to generate pre- OCs. (E–F) CSF1R and 
RANK mRNA expression (left hand side) and ChIP assay for H3K4me3 at promoter regions (right- hand side) of CSF1R and RANK genes in either (E) 
CD14+ MOs before and after 25 ng/mL M- CSF overnight stimulation (CD14+ pre- OCs) and (F) in freshly isolated donor- matched CD14+ MOS and 
CD14−CD16−CD11c+ myeloid cells. Bars show mean±SD. Data were analysed with two- way analysis of variance (ANOVA) for paired data and Sidak’s 
multiple comparisons test or paired Wilcoxon t- test (n=3–4 in E and n=6 in F). *p≤0.05; **p≤0.01. (G) Representative image of TRAP staining and 
quantification of TRAP+ MNCs/well of CD14+ pre- OCs and CD11c+ pre- OCs after 72 hours of 25 ng/mL RANK- L. Dotted lines indicate donor- matched 
samples. Data were analysed with Mann- Whitney test (n=4). *p≤0.05.
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of the TNF inhibitor etanercept27 reversed osteoclastogenesis 
(online supplemental figure S3A,B).
To characterise the time- dependence of this effect of TNF, 
CD14+ pre- OCs were stimulated with suboptimal levels of 
RANK- L that resulted in the appearance of mono- nucleated and 
bi- nucleated TRAP+ cells after 72 hours stimulation. The addi-
tion of TNF at this 72 hours time- point did not inhibit osteoclas-
togenesis (online supplemental figure S4A,B) but rather caused 
an increase in OCs (online supplemental figure S4C), consistent 
with many previous studies.28 Therefore, the kinetics of expo-
sure to TNF are critical for its effect on differentiation of CD14+ 
pre- OCs into mature OCs; with precursors initially having to 
commit to the OC lineage before there is a positive synergy 
between RANK and TNF.
To investigate the molecular mechanism responsible for early 
TNF exposure- mediated inhibition observed in CD14+ pre- 
OCs, we examined the epigenetic state of the RANK promoter 
and the resulting transcript and protein expression. On 4 hours 
Figure 2 Tumour necrosis factor (TNF) over- rides receptor activator 
of nuclear factorkappa- B ligand (RANKL)- driven osteoclastogenesis 
of CD14+ pre- osteoclasts (OCs) but not CD11c+ pre- OCs. (A–B) 
Freshly isolated peripheral blood mononuclear cells (PBMCs) were 
stained for flow cytometry and CD16−CD14+ monocytes (MOs) and 
CD14−CD16−CD11c+ precursors were sorted, incubated overnight with 
25ng/mL macrophage- colony stimulating factor to generate pre- OCs, 
and then differentiated into OCs for 7 days with 25 ng/mL RANK- L 
(MR) ±10 ng/mL TNF (MRT). (A) Representative digital reconstructed 
TRAP stained wells at 4× with boxed 10× magnification and (B) 
quantification of numbers of TRAP+ multinucleated cells (MNCs) per 
well. Data were analysed with two- way analysis of variance (ANOVA) 
and Holm- Sidak’s multiple comparisons test for paired data (n=3). 
*p≤0.05. Error bars show mean±SD of n=3. (C–D) CD14+ MOs and 
CD14−CD16−CD11c+ precursors were magnetically enriched, seeded 
onto mineral- coated wells, and differentiated into OCs for 14 days as in 
(A,B). (C) Digital images of resorption pits (mineral substrate in black; 
resorption pits in white) and (D) % of resorption. Statistical analysis was 
performed using two- way ANOVA and Sidak’s multiple comparisons test 
for paired data. Error bars=mean±SD of n=3. **p≤0.01.
Figure 3 Tumour necrosis factor (TNF) mediates epigenetic 
modification of the receptor activator of nuclear factor kappa-Β (RANK) 
promoter and controls RANK transcription and expression in CD14+ 
pre- osteoclasts (OCs). (A–F) Enriched CD14+ monocytes (MOs) were 
incubated overnight with 25 ng/mL to generate CD14+ pre- OCs. OCs 
were differentiated in the presence of RANK- ligand (RANK- L)±TNF. 
(A) Quantification of number of TRAP+ multinucleated cells (MNCs)/
well after 6 days of culture in increasing concentrations of RANK- L (25, 
50 or 100 ng/mL)±10 ng/mL TNF. Error bars show mean±SD of n=3. 
Data were analysed with two- way analysis of variance (ANOVA) and 
Tukey’s multiple comparisons test. ****p≤0.0001. (B) Quantification of 
TRAP+ MNCs/well after 6 days of 25 ng/mL RANK- L±TNF at different 
concentrations (0.1, 1 or 10 ng/mL). Bars=mean±SD of n=3. Data 
were analysed with Friedman test with Dunn’s multiple comparisons 
test, comparing to 0 ng/mL TNF. **p≤0.01. (C–F) CD14+ pre- OCs 
were differentiated in the presence of 25 ng/mL macrophage- colony 
stimulating factor (M- CSF)+25 ng/mL RANK- L (MR) or MR +10 ng/
mL TNF (MRT). (C) ChIP assay for H3K4me3 at the RANK promoter 
(left- hand side) and at the CSF1R promoter (right- hand side) on 
CD14+pre- OCs (0 hour) and after 4 hours MR or MRT stimulation. Bars 
show mean±SD of n=4. Data were analysed with two- way ANOVA 
for paired data and Sidak’s multiple comparisons test. *p≤0.05. (D) 
mRNA expression of RANK was evaluated at 0, 4, 12, and 24 hours 
after cytokine addition on CD14+ pre- OCs. Data were analysed with 
two- way ANOVA and Dunnet’s multiple comparisons test. **p≤0.01; 
***p<0.001; n=4. (E) Representative histograms of uptake of 
fluorescent RANK- L (RANK- LPB; black lines) after 72 hours of MR or 
MRT stimulation. Grey filled lines indicate unstained controls. (F) 
Graph shows quantification of RANK- LPB uptake; ΔMFI was calculated 
by subtraction of the unstained background fluorescence. Statistical 
significance was assessed via one- way ANOVA and Holm- Sidak’s 
multiple comparisons test. **p≤0.01; n=3. (G) CD14+ pre- OCs and 
CD11c+ pre- OCs were stimulated with MR or MRT for 4 hours. Graphs 
show RANK and CSF1R mRNA fold change, calculated by normalising to 
values at 0 hour prior stimulation (on pre- OCs after overnight M- CSF). 
Statistical significance was calculated using 2- way ANOVA for paired 
data and Sidak’s multiple comparisons test. **p≤0.01 *p≤0.05. Error 
bars show mean±SD of n=5.
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stimulation with RANK- L, CD14+ pre- OCs displayed enhanced 
H3K4me3 at the RANK promoter, with subsequent increased 
RANK transcript at 12 hours and 24 hours (figure 3C,D). The 
simultaneous addition of TNF with RANK- L suppressed this 
enhanced H3K4me3 and upregulation of transcript (figure 3C,D). 
This correlated with suppression of RANK expression at the cell 
surface (figure 3E,F). Notably, H3K4me3 levels at the CSF1R 
promoter and CSF1R transcripts were unaltered on RANK- L 
±TNF stimulation (figure 3C and online supplemental figure 
S5). As noted before, in contrast to CD14+ pre- OCs, CD11c+ 
pre- OCs were not sensitive to the TNF inhibition (figure 2). To 
investigate the disconnect between the two cell types, we eval-
uated the transcriptional expression of RANK post- TNF treat-
ment in donor- matched CD14+ pre- OCs and CD11c+ pre- OCs. 
Simultaneous addition of TNF with RANK- L suppressed the 
level of RANK in CD14+ pre- OCs but not in CD11c+ pre- OCs 
(figure 3G). Combined, these data suggest that TNF- mediated 
signalling in CD14+- derived OC precursors, but not CD14−C-
D16−CD11c+ precursors, epigenetically modulates the RANK 
locus, resulting in loss of transcript and protein expression.
TNF over-rides RANKL-driven osteoclastogenesis of CD14+ 
circulating precursors via a TNFR1 and canonical NF-κB 
pathway
RANK- L and TNF belong to the same TNF superfamily; stimula-
tion of their respective receptors results in activation of NF-κB. 
However, TNF stimulation of TNFR1 and TNFR2 primarily 
leads to activation of the canonical and non- canonical NF-κB 
pathways, respectively.29 30 RANK- L stimulation of RANK 
predominately leads to the activation of the non- canonical 
NF-κB pathway.31 TNFR1 and TNFR2 are expressed on both 
Figure 4 Tumour necrosis factor (TNF) over- rides receptor activator of nuclear factorkappa-Β ligand (RANKL)- driven osteoclastogenesis of CD14+ 
pre- osteoclasts (OCs) via a TNFR1 and canonical NF- kB pathway. (A) Freshly isolated peripheral blood mononuclear cells (PBMCs) were stained for 
flow cytometry. Representative histograms showing TNFR1 and TNFR2 expression on CD14+ monocytes (MOs) and CD14−CD16−CD11c+ precursors 
and quantification of Δmean fluorescence intensity (MFIs) (calculated by subtracting the MFI of the TNFR to the relative MFI of the isotype control). 
Cells were pre- gated on single Lin−(CD3−CD19−CD15−CD56−) HLA- DR+. Dotted lines indicate donor- matched samples. Data were analysed with 
Wilcoxon matched- paired signed rank test (n=6). *p≤0.05. (B–F) CD14+ pre- OCs were differentiated in the presence of 25 ng/mL macrophage- 
colony stimulating factor+25 ng/mL RANK- L (MR) or MR +10 ng/mL TNF (MRT). (B) Quantification of numbers of TRAP+ MNCs/well (top graph) 
and % of resorbed area (bottom graph) calculated, respectively at day 7 and day 10 of MR or MRT cultures±antibody blocking TNFR1 or TNFR2 
(αTNFR1 and αTNFR2) or±the respective isotype controls (iso1 and iso2, respectively). Statistical significance was assessed with two- way analysis 
of variance (ANOVA) and Sidak’s multiple comparisons test, comparing all data to MR. Error bars=mean±SD of n=3. ***p<0.001, ****p<0.0001. 
(C) Representative digital reconstructed wells of TRAP staining and 10× magnifications (in purple) at day 7 (top) and mineral- coated wells (mineral 
substrate in black; resorption pits in white) at day 10 (bottom) of CD14+- derived OC culture. (D) Representative digital images of resorption assay at 
day 10, (E) quantification of % of resorbed area and (F) quantification of numbers of TRAP+ MNCs/well differentiated at day 7 with MR or MRT in the 
presence of an IKK-β inhibitor at 100 nM (MRT+100 nM) or 300 nM (MRT+300 nM) or+vehicle control (MRT+v). (E) Mean±SD of one representative 
experiment of n=4. Data in (F) were analysed with Friedman analysis of variance and Dunn’s multiple comparisons test. *p≤0.05; **p≤0.01. Error 
bars indicate mean±SD of n=3.
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CD14+ circulating MOs and CD14−CD16−CD11c+ myeloid 
cells (figure 4A).32 However, the level of TNFR1 is significantly 
lower on CD14−CD16−CD11c+ precursors (figure 4A). To assess 
the role of TNFR1 and TNFR2 in the TNF- mediated inhibition 
of OC differentiation from CD14+ MOs, we utilised TNFR1- 
specific and TNFR2- specific blocking antibodies. Blockade of 
TNFR1, but not TNFR2, mitigated the inhibitory effect of TNF 
on OC numbers and function (figure 4B,C). Given that TNFR1- 
mediated signalling is through the canonical NF-κB pathway 
(via the IκB kinase (IKK) complex formed by IKK-α, IKK-β 
and NEMO),30 we used a selective IKK-β inhibitor (TPCA-1) 
to specifically block this signalling cascade. Inhibition of IKK-β 
significantly suppressed the ability of TNF to inhibit OC differ-
entiation and activation (figure 4D–F). Importantly, TPCA-1 did 
not affect RANK- L- induced osteoclastogenesis or their resorp-
tive capacity (figure 4D,E), as this is primarily driven by non- 
canonical NF-κB signalling.33–35 TNFR1- mediated signals have 
also been associated with initiation of caspase cascades and subse-
quent apoptosis. TNF stimulation of CD14+ pre- OCs resulted in 
decreased caspase activation and no change in apoptosis levels 
(online supplemental figure S6). Interestingly, RANK- L- mediated 
differentiation of CD14+ pre- OCs for 72 hours resulted in 
upregulation of TNFR2 (online supplemental figure S7A,B). 
This corresponded with TNFR2- dependent TNF- mediated 
enhancement of OC differentiation in these precommitted OC 
precursors (online supplemental figure S7C,D). Taken together, 
our data reveal a fundamental dual role of TNF in enhancing 
or blocking OC differentiation. Early exposure to concomitant 
RANK- L and TNF activates the canonical NF-κB pathway via 
TNFR1 and halts osteoclastogenesis; in contrast, later TNF 
addition on precommitted pre- OCs aids RANK- L and osteoclas-
togenesis via TNFR2 and non- canonical NF-κB signalling. This 
may also partly explain why circulating CD14−CD16−CD11c+ 
precursors are unresponsive to TNF- mediated inhibition, given 
their lower levels of TNFR1 (figure 4A).
Patients with RA have a perturbed myeloid compartment and 
TNF does not negatively regulate OC differentiation
Cell in the myeloid compartment and TNF play key roles in RA 
pathology. Analysis of circulating CD14+ MOs and CD14−C-
D16−CD11c+ precursors in our RA cohort showed that while 
the abundance of CD14+ MOs was not affected in RA, CD14−C-
D16−CD11c+ precursors were significantly reduced (figure 5A). 
Figure 5 Patients with rheumatoid arthritis (RA) have epigenetically perturbed CD14+ monocytes with increased receptor activator of nuclear factor 
kappa-Β (RANK) expression. (A) Freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy controls (HC) and RA were stained for 
flow cytometry and percentages of CD14+ MOs and CD14−CD16−CD11c+ precursors in PBMCs were calculated. Statistical significance was calculated 
using unpaired t- test (n=10 HC and n=14 RA). ****p≤0.0001. (B) Diffbind normalised peak intensity heatmap highlighting the size and consistency 
of differences between HC and RA. Samples are given by column and the 6763 significantly differential peaks (<5% FDR) by row. Colour intensity 
indicates row scaled (z- score) peak intensity with blue as low and red as high. Rows have been hierarchically clustered using Spearman distances. (C) 
Network plot of the enriched (p<0.0001) Gene Ontologies for the 6763 significantly differential peaks (FDR<5%). Nodes denote Gene Ontologies and 
edges join nodes where >50% significant peak containing genes are shared. Node colour intensity represents enrichment (−log10p) and node size 
the number of significant peaks containing genes. Representative names for node clusters are given. (D) Genome Browser traces of the RANK, TNFR1 
and TNFR2 H3K4me3 promoter peaks. (E) Input normalised peak intensity boxplots for the RANK, TNFR1 and TNFR2 promoter peaks (top) and relative 
mRNA expression measured on freshly isolated CD14+ monocytes (MOs) from HC and RA (bottom). Unadjusted diffbind p values are given in the top 
graph. Two- way analysis of variance (ANOVA) and Sidak’s multiple comparisons test was used for the analysis in the bottom graph. Graph shows box 
and whiskers with min to max of n=4 for HC and n=11 for RA. *p≤0.05; **p≤0.01. (F) Freshly isolated PBMCs from HC and RA were stained for flow 
cytometry to evaluate TNFR1 and TNFR2 expression. Box and whiskers show TNFR1 and TNFR2 expression on CD14+ MOs in Δmean fluorescence 
intensity (MFIs) for n=13 each group. Error bars shows min to max variation.
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This is consistent with previous studies showing reduced mDCs 
in both RA bloodstream and inflamed synovium.36 Whether this 
is due to their rapid recruitment and differentiation in situ or to 
their minor contribution to bone erosion in RA pathology is not 
known. However, recent independent studies both in the blood 
and the synovium have interrogated the molecular signature of 
both CD14+ MOs and CD1C pre- DC (which are the closest 
subset to our CD11c+ myeloid precursors) in RA.37 38 Analysis 
of this publicly available data revealed a high transcriptional 
correlation between blood and synovial CD1C cells (online 
supplemental figure S8A), indicating a common cell lineage 
origin. Notably, among the most differentially expressed gene, 
RANK was dramatically upregulated in the CD1C synovial coun-
terpart, compared with circulating cells (online supplemental 
figure S8B). These data taken together suggest that CD11c+ 
(or CD1C cells) are present in the inflamed synovium and have 
the molecular potential to differentiate into OC; although their 
contribution to RA bone erosion remains elusive.
In contrast, although the abundance of circulating MOs was 
unaffected in RA, prior studies have shown that their transcrip-
tional profile is different from non- inflammatory controls.39 We 
therefore hypothesised, having shown that the epigenetic status 
of CD14+ MOs controls the inhibitory TNF effect, that RA blood 
CD14+ MOs may exhibit a distinct epigenetic state. To gain 
further insight into this dysregulation, genome- wide H3K4me3 
histone modification was investigated using ChIPseq. Compar-
ison between patients with biological naïve RA with moderate to 
severe disease (DAS28=4.44±0.9) and healthy control CD14+ 
MOs, identified 6764 significantly differential peaks (adjusted 
p>0.05) (figure 5B). Pathway enrichment and network analysis 
revealed that these differential peaks of RA MOs were primary 
associated with cell differentiation and development pathways 
(figure 5C and online supplemental dataset 1).
Based on the observed changes in RANK, CSF1R, TNFR1 
and TNFR2 in healthy MOs, a focused analysis of the ChIPseq 
data showed that there was a significant increase of H3K4me3 in 
RA CD14+ MOs at the RANK and TNFR1 loci but not TNFR2 
and CSF1R (figure 5D,E). This corresponded with an increased 
level of RANK transcript but not TNFR1 (figure 5E). However, 
increased TNFR2 transcript was detected in RA CD14+ MOs 
(figure 5E), although this did not correspond to a significant 
increase in cell surface expression (figure 5F).
Given the observed altered epigenetic landscape in RA MOs 
and the strong evidence that TNF drives joint destruction in RA, 
we hypothesised that the homoeostatic effect of TNF on circu-
lating myeloid cells would be perturbed in RA and could thus 
promote OC- mediated erosive pathology. To assess the impact 
of this on responsiveness to TNF, CD14+ pre- OCs from RA and 
healthy controls were differentiated in the presence of RANK- 
L±TNF. While TNF consistently inhibited osteoclastogenesis 
in healthy controls, we observed a significant decrease in the 
capacity of TNF to inhibit osteoclastogenesis in patients with RA, 
with a certain degree of variance (figure 6A). In particular, 44% 
manifest TNF- mediated inhibition (responders), whereas in 56% 
of patients TNF was unable to inhibit osteoclastogenesis (non- 
responders; figure 6A,B). Remarkably, TNF had an enhancing 
pro- osteoclastogenic effect in 45% of the non- responder group. 
To further investigate the heterogeneity in the patients with 
RA, ChIPseq data of those patients that showed TNF- mediated 
inhibition (responders) and those that did not (non- responders) 
were compared. This analysis revealed that there were 4172 
significantly differential peaks (figure 6C). Pathway enrichment 
showed that abundant peaks in RA MOs of the non- responder 
group were associated with transmembrane receptor protein 
kinase pathways and DNA- binding transcription repressor 
activity pathways (figure 6D and online supplemental dataset 2). 
Among the transmembrane receptor protein kinase pathways, 
CSF1R was found to be lower in the non- responders compared 
with the responders. STRING analysis of the identified trans-
membrane receptor protein kinase pathway associated genes 
also provided a link between CSF1R and NRP1 (figure 6E). 
Interestingly, NRP1 is known to act as a coreceptor for vascular 
endothelial growth factor (VEGF)- R40 in MOs/macrophage, 
and VEGFR expression and VEGF- mediated signalling has been 
associated with MO differentiation into OCs.41 42 Evaluation of 
RA patient serum revealed that high levels of VEGF correlate 
with response to TNF (figure 6F). Combined, these data suggest 
that in a proportion of patients with RA the high levels of VEGF 
correlate with a perturbation in the myeloid compartment, such 
that TNF homoeostatic control is diminished, thereby enhancing 
the potential for maturation of OCs derived from the circulating 
MO pool when they enter the joint.
DISCUSSION
Our data reveal an unexpected role for TNF in the control of 
cell fate decisions in the myeloid compartment that regulates 
OC development and subsequent activation. In homoeostatic 
conditions, TNF can directly over- ride OC differentiation 
signals to which circulating myeloid precursors would other-
wise respond. Furthermore, we have identified a specific human 
Lin−HLA−DR+CD14−CD16−CD11c+ precursor population 
that preferentially differentiates down the OC lineage, and that, 
based on its epigenetic state, is unresponsive to homoeostatic 
regulation imparted by TNF. In RA, a proportion of patients 
with moderate/severe disease activity exhibit failure of this regu-
latory role of TNF with some patients even exhibiting acceler-
ated osteoclastogenesis on TNF exposure at this very early time 
point in the precursor differentiation pathway. This perturbed 
response is due to an altered MO epigenetic landscape. Taken 
together, our findings provide a novel, previously unrecognised 
hierarchy between TNF cytokine family members regulating cell 
fate decisions in both health and disease, which is mediated via 
the epigenetic set- point of circulating precursors defining their 
capacity to respond to cytokine combinations in the local milieu.
Our finding that homoeostatic TNF can control MO, but 
not other myeloid precursor differentiation in osteoclastogenic 
rich environments defines a paradigm in which priming of cells 
within the circulating myeloid compartment creates either a 
permissive or non- permissive epigenetic state that allows cells to 
differentiate down the most appropriate lineage. It is however, 
currently unclear how this epigenetic state is achieved in circu-
lating MOs or how TNF drives additional changes, and thus 
the role of specific histone methyltransferase and/or demeth-
ylases should be evaluated in future studies.43 Previous studies 
have demonstrated that CD14+ MO- derived immature DC- like 
cells have the ability to transdifferentiate into OCs more effi-
ciently than CD14+ MO progenitors.19 44 Note however, that 
circulating pre- DCs are the only cell subset capable of gener-
ating classical DCs while CD14+ MO can only generate DC- like 
cells.7 Our findings provide the first evidence that circulating 
human Lin−HLA−DR+CD14−CD16−CD11c+, which can also 
phenotypically be associated with the pre- DC population, can 
differentiate down the OC lineage. Whether Lin−HLA−DR+C-
D14−CD16−CD11c+/pre- DCs are the missing OC precursor in 
humans remains to be conclusively determined.
Based on this work, we suggest that in a normal self- 
resolving inflammatory event (which can include sterile/acute 
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inflammation), Lin−HLA−DR+CD14−CD16−CD11c+ cells 
recruited to bone will still respond to the cytokine rich local 
environment by differentiating down the OC lineage and thus 
help maintain skeletal health. In contrast, circulating CD14+ 
MOs are in a non- permissive state and are inhibited from 
contributing to the OC pool. We recognise the limitations of 
our study; in that we have used in vitro methods to evaluate 
cell fate decisions within the myeloid compartment. Evidence 
to further support this theory would require human in vivo/
ex vivo cell fate mapping studies to determine which precur-
sors (Lin−HLA−DR+CD14−CD16−CD11c+ or CD14+ MOs) 
contribute to the bone- associated OC pool. Unfortunately, 
these assays are not currently possible. Further studies will 
need to define a way of identifying Lin−HLA−DR+CD14−C-
D16−CD11c+—versus MO- derived OCs in situ to better under-
stand this alternative route to mature OCs. Moreover, they 
Figure 6 Tumour necrosis factor (TNF) does not inhibit CD14+- derived osteoclast (OC) differentiation in a portion of patients with rheumatoid 
arthritis (RA). (A–B) CD14+ pre- OCs were differentiated for 7 days into OCs in the presence of 25 ng/mL macrophage- colony stimulating factor (M- 
CSF) and receptor activator of nuclear factorkappa-Β ligand (RANK- L) (MR) ±10 ng/mL TNF (MRT). (A) Percentage of inhibition of OC differentiation 
was calculated as 100−[(100×#OCs(MRT))/#OCs(MR)] in patients with healthy controls (HC) and RA. Light red dots indicate non- responder group and 
light blue dots the responder using in subsequent ChIP analysis. Data were analysed with Mann Whitney test (n=16). **p≤0.01. (B) Representative 
reconstructed wells and 10× magnifications of TRAP staining of one representative HC, one RA non- responder and one RA responder, in MR and 
MRT conditions. OCs=TRAP+ multinucleated cells, MR=M- CSF+RANK L, MRT=M- CSF+RANK- L+TNF. (C) Volcano plot for RA responders versus non- 
responders across the 65 717 consensus peaks. Significantly differential peaks (<5% FDR) are highlighted in red. Positive fold changes denote greater 
peak intensity in RA responders. (D) Boxplot of the 35 significantly differential peaks (<5% FDR) between RA non- responders and RA responders 
that are associated with the top enriched (p<0.0001) gene ontology transmembrane receptor protein kinase activity. Individual peaks (and the gene 
they are associated with) are given on the x- axis and the Diffbind normalised peak intensity (per peak z- score) is given on the y- axis. Separate boxes 
are provided for non- responder samples (n=3) and responder samples (n=3). (E) STRING network plot of the genes in the transmembrane receptor 
protein kinase activity gene ontology. Nodes represent proteins and edges joining nodes represent protein–protein associations (known interactions; 
blue—curated data, pink—experimentally determined. Predicted interactions; green—gene neighbours. Other interaction; black—coexpression). 
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should also investigate the global molecular and epigenetic 
signature of Lin−HLA−DR+CD14−CD16−CD11c+ and CD14+ 
precursors cells, and their respective mature OCs, to ultimately 
identify the specific precursor cells and molecular mechanisms 
involved in inflammatory joint destruction.
Anti- TNF therapy is one of the gold standard treatments 
for multiple inflammatory- mediated diseases including RA. It 
is paradoxical however, given that TNF inhibitors are known 
to be antierosive,45 that we show an antierosive effect for TNF 
itself via a homoeostatic pathway in health. Crucially, we do 
show that in a proportion of patients with RA with have higher 
levels of VEGF, there is a failure in this homoeostatic pathway. 
Leading us to hypothesise that such failure may represent a route 
MO preconditioning and subsequent accelerated erosion in a 
subset of patients. Characterising the nature of such a failure 
may offer future therapeutic opportunities. For instance, deter-
mining how to re- engage this regulatory pathway may lead to 
new antierosive therapeutics that have the ability to re- sensitise 
some patients with RA to the regulatory element of TNF biology. 
This could also have the added value of reducing the capacity 
of TNF, produced for example during RA synovitis, to sensitise 
early precursors down the OC pathway. Finally, the newly iden-
tified Lin−HLA−DR+CD14−CD16−CD11c+ precursor route 
to mature OCs represents an unexplored independent mecha-
nism to mature OCs and potentially erosive progression in RA. 
A detailed understanding of this new pathway could reveal an 
as yet untargeted pathway in the disease context. In summary, 
these data support further evaluation of these pathways in RA 
and other diseases associated with bone pathology to discover 
their utility as alternative therapeutic strategies to abrogate 
erosive progression.
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Supplementary materials and methods 
Blood collection and cell isolation 
Blood from healthy individuals and RA patients was collected in lithium heparin 
vacuum blood tubes (BD Vacutainer LH, 170 IU). For certain RA patients, blood for serum 
separation was also collected (BD Vacutainer SST II Advance). Blood samples from patients 
diagnosed with RA (with a diagnosis meeting the 2010 ACR/EULAR RA criteria) were 
collected at Rheumatology clinics (Glasgow, UK); all patients were naïve to TNF-biologics 
and had moderate to severe disease based on their Disease Activity Score (DAS28). Table S1 
summarizes the characteristics of our study population. The study protocol was approved by 
the West of Scotland Research Ethical Committee (11/S0704/7). All the donors provided 
signed informed consent. Alternatively, buffy coat was obtained from the Scottish National 
Blood Transfusion Service (approved by Glasgow NHS Trust-East Ethics Committee). 
Peripheral blood mononuclear cells (PBMCs) were extracted by density gradient separation 
using Ficoll-paque PLUS (GE Healthcare Life Science). CD14+ monocytes and CD11c+ 
precursors were magnetically enriched from PBMCs using EasySep™ Human CD14 Positive 
Selection Kit and EasySep™ Human Myeloid DC Enrichment Kit (STEMCELL 
Technologies) respectively. Purity was assessed via flow cytometry staining and showed 
purity≥96%.  
 
Cell cultures and osteoclast differentiation and analysis 
Freshly isolated PBMCs, magnetically enriched CD14+ monocytes and CD11c+ 
precursors (purity≥96%), as well as fluorescently sorted populations (purity≥99%), were re-
suspended at 1x106/ ml in complete α-MEM medium (supplemented with 10% of heat 
inactivated foetal bovine serum (FBS), 0.02 mML-glutamine, 10 units/ml penicillin, 0.1 
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mg/ml streptomycin) (Invitrogen, Thermo Fisher Scientific), plated at density of 1x105/well 
in 96-well plates either on plastic or on mineral-coated plates (Corning osteo-assay surface 
microplate) and stimulated with 25 ng/ml macrophage–colony-stimulating factor (M-CSF; 
Peprotech). After overnight incubation cells were defined as CD14+ pre-osteoclasts (pre-
OCs) and CD11c+ pre-OCs (approximately 18h) and used for down-stream applications. 
Osteoclasts were differentiated by stimulating pre-OCs with 25ng/ml (unless where otherwise 
stated) receptor activator of nuclear factor kappa-B ligand (RANK-L), alongside 25ng/ml M-
CSF. Tumor necrosis factor alpha (TNF) was used at 0.1, 1, and 10 ng/ml and added at 
different time points during osteoclastogenesis, as specified in figure legends. Medium was 
refreshed every 3-4 days. For cultures on plastic, osteoclast differentiation was assessed by 
fixation of cells and staining with tartrate-resistant acid phosphatase (TRAP) kit (Sigma-
Aldrich), in accordance with the manufacturer’s instructions. For the resorption assay, cells 
were removed from mineral-coated plates using a 10-15% sodium hypochlorite solution 
(Sigma-Aldrich) and the mineral substrate left to air dry. Reconstructed digital images of the 
entire well were acquired using an EVOS FL Auto Cell Imaging System (Life Technologies). 
Osteoclasts were identified as TRAP+ multinucleated (nuclei≥3) cells (MNCs) and counted 
using Fiji software (ImageJ). Resorption was calculated using Fiji software (ImageJ) by 
converting the images into 8-bit and setting the threshold at 223 to 254; resorption areas were 
calculated as % of the total area of the well.  
 
Signalling inhibition and TNF receptor blockade during osteoclastogenesis  
TNF receptor fusion protein etanercept (Enbrel, Amgen) was added to osteoclast 
cultures at 1, 10, or 50 μg/ml alongside with TNF. Additionally, purified antibody 
specifically recognizing TNF receptor 1 (mouse anti-human CD120a; αTNFR1; eBioscience) 
and TNF receptor 2 (rat anti- human CD120b; αTNFR2; BioLegend) were added to 
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osteoclast cultures in the presence of RANK-L ± TNF. Appropriate isotype antibody controls 
were purchased from BioLegend and used as negative controls. All antibodies and isotypes 
were used at 10 μg/ml. In some experiments, TPCA-1 ([5-(p-Fluorophenyl)-2-
ureido]thiophene-3-carboxamide; Sigma-Aldrich) was used to specifically inhibit IκB kinase-
2 (IKK-2; IC50 = 17.9 nM). TPCA-1 was added at 100 and 300nM at the beginning of the 
osteoclast culture alongside 25 ng/ml RANK-L ± 10 ng/ml TNF. After 24h the inhibitor was 
washed off and medium replaced with 25 ng/ml RANK-L ± 10 ng/ml TNF. 0.06% Dimethyl 
sulfoxide (DMSO) was used as vehicle control.   
 
Cell preparation for flow cytometry applications  
Freshly isolated PBMCs were suspended in DPBS supplemented with 1% FBS, 0.1% 
NaN3 and 5mM EDTA and stained for flow cytometry. Alternatively, freshly enriched 
CD14+ monocytes were incubated overnight with 25ng/ml M-CSF to generate CD14+ pre-
OCs (0h) and then stimulated with 25 ng/ml RANK-L ± 10 ng/ml TNF for 72h. Control wells 
received M-CSF alone. Cell were taken at 0 and 72h and stained for flow cytometry. To sort 
specific populations, PBMCs were stained with flow cytometry antibodies in sterile DPBS 
supplemented with 1% FBS and 2mM EDTA and sorted using an BD FACSAria III cell 
sorter with an 85µm nozzle (BD Bioscience). Cells were sorted into tubes containing 
complete α-MEM, re-suspended at 1x106 cells/ml and incubated overnight with 25ng/ml M-
CSF for downstream osteoclast cultures. Post-sorting check assessed purity≥99%. Antibody 
staining was performed in the dark for 15 minutes at 4˚C. Additional incubation for 20 
minutes at 4˚C with PerCP/Cy5.5 Streptavidin (BioLegend) was performed where required. 
Washed cells were acquired with an LSR II cytometer (BD Bioscience) and data analysed 
with a Flowjo 10.0.5 software (Tree Star).  
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Antibodies used for flow cytometry  
Anti-human antibodies used for flow cytometry applications are listed below: APC-
Cy7 CD14 (M5E2; BioLegend), PE-CF594 mouse anti-human CD14 (MφP9; BD 
Bioscience), V500 CD16 (3G8; BD Biosciences), PE-Cy7 HLA-DR (G46-6; BD 
Biosciences); Alexa Fluor-700 CD11c (B-ly6; BD Bioscience), Brilliant Violet-605 CD123 
(6H6; BioLegend), biotin TNFR1/CD120a (MABTNFR1-B1; BD Bioscience), Alexa Fluor-
647 TNFR2/CD120b (hTNFR-M1; BD Bioscience), PE CD3 (UCHT1; BD Bioscience), PE 
CD19 (J3-119; Beckman Coulter), PE CD56 (MY31; BD Biosciences); PE CD15 (VIMC6; 
Miltenyi Biotec); APC CD80 (2D10; BioLegend); FITC CD64 (10.1; BioLegend); Brilliant 
Violet 421 CD206 (15-2; BioLegend). Mouse IgG2a (G155-178; BD Bioscience) and rat 
IgG2a (A95-18; BD Biosciences) were used as isotype controls for TNFR1 and TNFR2 
respectively.  
 
Labelling of RANK-L and fluorescent protein up-take 
Recombinant human soluble RANK-L (Peprotech) was re-suspended at 1 mg/ml in 
dH2O and labelled with Pacific Blue™ protein labelling kit, following the manufacturer’s 
instructions (Thermo Fisher Scientific). Concentration of the labelled cytokine (RANK-LPB) 
was assessed by Nanodrop and adjusted to 100μg/ml in 0.1% bovine serum albumin (BSA) in 
Dulbecco's phosphate-buffered saline (DPBS; Life Technologies, Thermo Fisher Scientific).  
CD14+ monocytes were differentiated into OCs for 72h in the presence of 25 ng/ml 
RANK-L ± 10 ng/ml TNF and then incubated at 37˚C for 1 hour with 100ng/1x106 cells 
RANK-LPB in complete α-MEM medium (no FBS). Medium alone was used as negative 
control. After the incubation, cells were washed and re-suspended in DPBS supplemented 
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with 1% FBS, 0.1% NaN3 and 5mM Ethylene-di-amine-tetra-acetic acid (EDTA) for flow 
cytometry analysis.  
 
Cytokine production analysis 
CD14+ monocytes, after overnight incubation, were stimulated with different 
combinations of 25ng/ml M-CSF, 25ng/ml RANKL, and 10ng/ml TNF. Granulocyte 
macrophage colony-stimulating factor (GM-CSF; Peprotech) was used at 100 ng/ml. After 6 
days medium was removed and replaced with media containing vehicle control or 100ng/ml 
lipopolysaccharide (LPS from Salmonella Minnesota R595; InvivoGen). After 18h 
supernatants were stored, and cytokine production was assessed. Alternatively, CD14+ 
monocytes and CD11c+ precursors were magnetically enriched, incubated overnight with 
25ng/ml M-CSF to generate pre-OCs and then stimulated for 72h with 25ng/ml RANKL ± 
10ng/ml TNF. Supernatants were collected and cytokine concentration assessed using the 
Meso Scale Discovery technology (Meso Scale Diagnostics). Specifically, a V-PLEX Pro-
inflammatory Panel 1 Human Kit (Meso Scale Diagnostics) was used to determine 
concentrations of IL-10, IL-12p70, IL-1β, IL-6, and IFNγ in cell supernatants, following 
manufacturer’s instructions. Analysis was performed using the MSD Discovery Workbench 
analysis software (Meso Scale Diagnostics). 
 
RNA isolation and quantitative RT-PCR 
Cells were lysed in RLT buffer (Qiagen) containing 1% beta-mercaptoethanol. 
mRNA was extracted according to the manufacturer’s instructions using the RNeasy Micro 
Kit (Qiagen) and eluted in 15 μl RNAse-free H2O. cDNA was synthesized using High 
capacity cDNA reverse transcription kit (Applied Biosystems, Thermo Fisher Scientific).  A 
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quantity of 1 ng cDNA was taken for RT-qPCR analysis using Power SYBR Green PCR 
Master Mix (Applied Biosystems, Thermo Fisher Scientific), and a QuantStudio 6 machine 
(Thermo Fisher Scientific).  A quantity of 1 ng cDNA was taken for RT-qPCR analysis using 
Power SYBR Green PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific), and a 
QuantStudio 6 machine (Thermo Fisher Scientific). Relative gene expression and fold change 
was calculated using the comparative CT method[1]. ΔCT values were calculated as CT gene of 
interest – CT housekeeping gene for each sample. The ΔCT is then converted to linear relative gene 
expression using the following formula 2-ΔCT. Fold change was measured as 2-ΔΔCT, where 
ΔΔCT corresponded to ΔCT control sample– ΔCT treated sample. Oligonucleotides were designed in 
house and listed in Table S2. Primers for RANK and GAPDH were designed on exon span 
junctions.  In order to avoid genomic contamination, endogenous DNA was digested using 
RNase-Free DNase set during mRNA extraction, as described in the manufacturer’s 
instructions (Qiagen).  
 
Chromatin Immunoprecipitation (ChIP) 
Cells were fixed in 1% formaldehyde for 10 minutes at room temperature, followed 
by quenching with 125mM Glycine for 5 minutes. Cells were scraped and collected by 
centrifugation at 4˚C.  Pelleted cells were washed twice with cold DPBS (GIBCO, Thermo 
Fisher Scientific) and lysed in lysis buffer (20mM Hepes pH 7.6, 1% SDS, 1X Protease 
Inhibitor Cocktail and 10Mm Sodium butyrate).  Chromatin samples were sonicated for 14±2 
cycles of 30 sec ON/30 sec OFF with the Bioruptor Pico sonication device (Diagenode) until 
most of the DNA fragments were 100-600 bp long (average length 200 bp).  The sonicated 
samples were then centrifuged at ≥13000 rpm for 5 minutes at 4˚C to collect the supernatant 
containing the soluble chromatin fraction.  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219262–10.:10 2021;Ann Rheum Dis, et al. Ansalone C
 9 
For each IP, 20µl of Dynabeads Protein A (Invitrogen, Thermo Fisher Scientific) 
were used. For antibody conjugation, beads were washed in ChIP dilution buffer (1% Triton 
x-100, 1.2 mM EDTA, 16.7mM Tris buffer pH 8, and 167mM NaCl) containing 0.01% SDS 
and 0.1% BSA and incubated with H3K4me3 antibody (Merk Millipore (1.5ug/IP)) in the 
same buffer for 1hr at room temperature with rotation. After conjugation, beads were washed, 
and the chromatin added; conjugated beads and chromatin were incubated in ChIP dilution 
buffer on a rotator for 3h at 4˚C. After incubation, beads were washed once with ChIP 
washing solution 1 (2mM EDTA, 20mM Tris buffer (pH 8), 1% Triton x-100, 0.1% SDS, 
and 150mM NaCl), twice with ChIP washing solution 2 (2mM EDTA, 20mM Tris buffer (pH 
8), 1% Triton x-100, 0.1% SDS, and 500mM NaCl), and twice with ChIP washing solution 3 
(1mM EDTA, 10mM Tris buffer (pH 8)). Finally, the beads were eluted in 100µl elution 
buffer (0.5% SDS, 300mM NaCl, 5mM EDTA, and 10mM Tris (pH 8)) containing 200µg/ml 
Proteinase K (Sigma-Aldrich). De-crosslinking was done by incubating samples at 55˚C for 
1h followed by overnight at 65˚C. The supernatant containing the immunoprecipitated DNA 
was purified using Qiagen MiniElute PCR purification kit, following manufacturer 
instructions.  Eluted DNA was used for qPCR and ChIP-seq applications. Gene promoter 
regions were obtained using the UCSC Genome Browser; primers were designed in house 
and listed in Table S3. 
 
ChIP-seq data analysis  
ChIP-seq libraries were prepared using the NEB NEXT Ultra II DNA-library prep kit 
(E7645S for ChiP and E7600S for input) and samples were sequenced on an Illumina Next-
Seq to a mean depth of 38 million reads. The read length was 75pb SE. The read quality of 
ChIP-seq dataset was verified using fastQC (v0.11.7) with each sample showing a mean per 
base quality > 30 at all read positions. The data aligned to the human genome (GRCh38 
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version 94) using bowtie 2 (v2.3.5) with default parameters for indexing and alignment. A 
mean alignment of 28 million uniquely mapping reads per sample (74%) was observed. Per 
sample wig files were generated using the PeakRanger (1.18) wig command with format 
bam. Bigwigs were generated from the wig files using UCSC tools wigToBigWig (v4), with 
chromosome sizes as determined by UCSC tools faSize. The per sample H3K4me3 peaks 
were called with macs2 (v2.1.1.20160309) callpeak using the input BAM file for each sample 
as the control, a genome size of 2,945,849,067bp and specifying --format BAM. The 
alignment and peak data were inspected on the IGV genome browser (v2.7.2). Two samples 
(RA2 and RA4) showed high levels of noise (observable as non-peak aligned reads), low 
numbers of reads at peaks (10x lower than the mean) and low technical correlation with other 
samples. These samples were therefore excluded from the downstream analysis. Next, 
differential peaks between the HC and RA samples were called using the R (v3.6.2) package 
DiffBind (v2.14.0) using the per sample MACs broad peaks as Peaks and the per sample 
input BAM files as bamControl. The model was set to HC vs RA. All other parameters were 
left to default. DiffBind identified 6,763 significantly differential peaks at < 5% FDR from a 
consensus set of 75,425 peaks. The DiffBind normalised peak intensities were used for the 
downstream heatmap and GO analysis. The 6,763 differential peaks were annotated using 
Homer (v4.11.1) annotatePeaks with the databases organism human (v6.3), promoters human 
(v5.5) and genome hg38 (v6.4). The Gene Ontology (GO) enrichment was calculated using 
Homer findMotifs.pl inputting the entrez ID of the nearest TSS (within 50kb) for each peak 
(from the annotated peaks file) as the candidate genes. All other settings were left to default. 
Enriched ontologies were identified as p < 0.0001 and (to reduce database redundancy) a 
term size > 5 and < 250. The GO enrichment results are provided in supplementary dataset 1. 
To identify differential peaks between responders and non-responders, firstly, 
responder (R) samples were identified as having a percent of inhibition > 68% (RA3, RA7 
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and RA11) and non-responder NR) samples as < 25% (RA1, RA6 and RA10). Next 
differential peaks were identified using the methods as described above however with the 
model R vs NR. DiffBind identified 4,172 significantly differential peaks at < 5% FDR from 
a consensus set of 65,717 peaks. Differential peaks were annotated, and enriched GO 




The heatmap of the 6,763 differential peaks between HC and RA (figure 5A) was 
generated using the R library amap (v0.8-17). Rows were clustered using the function hclust 
with Spearman distances and mean reordering. Diffbind normalised peak intensities were row 
scaled into z-scores.  
To generate the network of enriched GO (figure 5C) the Homer enrichment results for 
biological process, molecular function and cellular component were concatenated and filtered 
to include only terms with an enrichment value < 0.0001 and between 5 and 250 genes with 
significant peaks. Each remaining ontology was considered a node and edges were drawn 
between two nodes where at least 50% of the genes with significant peaks were in common 
(Szymkiewicz-Simpson coefficient) and there were at least 5 overlapping genes with 
significant peaks. The network was drawn using the R package ggnet2 (v2.4) under default 
settings. To highlight the major functional groups, clusters with fewer than 5 nodes were 
removed, and representative names were given.  
To generate the candidate peak (RANK, TNFR1 and TNFR2) bar-plots (Figure 5C) 
the promoter consensus peak (as generated previously by Diffbind) for each gene was 
identified using IGV. Next the read count at each peak for each H3K4me3 and input sample 
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was determined using the Bedtools (v2.26) multicov function. The aligned library size for 
each sample was determined using Samtools (v1.7) view -c with -F 260. Next the counts per 
million (CPM) ((count / library size) x1,000,000) at each peak was determined for each 
H3K4me3 and input sample. Finally, the input normalised peak intensities were calculated 
as: H3K4me3 CPM – Input CPM.  
To create STRING networks we used the dedicated website (https://string-db.org) and 
the multiple proteins function under default settings[2]. 
 
Comparison between blood CD1C and Classical Monocyte populations.  
PBMC single cell RNA-seq dataset was obtained from GEO (GSE94820) as raw 
counts. These were then partitioned into the pre-identified CD1C and Classical Monocyte 
populations and differential expression performed using DESeq2. The data was then explored 
with Searchlight2 using an adjusted p < 0.01 and absolute log2 fold change >1 and the GO 
biological process database. All other settings were left to default.  
 
RA serum analysis 
Serum from RA patients was collected by centrifugation at 1200xG for 10’ minutes, 
aliquoted and stored at -80˚C. Serum VEGF was evaluated using a U-PLEX Human VEGF-A 
(Meso Scale Diagnostics). Analysis was performed using the MSD Discovery Workbench 
analysis software. 
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Statistical analysis 
Prism 6 (Graphpad) was used to perform all statistical analysis and statistical tests 






BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219262–10.:10 2021;Ann Rheum Dis, et al. Ansalone C
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219262–10.:10 2021;Ann Rheum Dis, et al. Ansalone C
 15 
  
Figure S2. CD11c+ pre-OCs produces IFNγ under TNF stimulation while CD14+ pre-
OCs produce pro-inflammatory cytokines. PBMCs were isolated and CD14+ monocytes 
(MOs) and CD11c+ precursors were magnetically enriched and incubated overnight with 
25ng/ml M-CSF to generate CD14+ and CD11c+ pre-OCs, following by 72h RANK-L 
stimulation ± TNF (25ng/ml and 10ng/ml respectively). Cell supernatants were analysed for 
IL-12, IL-1β, IL-6, and IFNγ concentration. Bars show mean±SD of n=3-4. Statistical 
analysis was done using paired 2-way ANOVA and Sidak’s multiple comparison tests. 
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Figure S5. TNF does not affect CSF1R expression. Enriched CD14+ monocytes (MOs) 
were incubated overnight with 25ng/ml to generate CD14+ pre-OCs. CD14+ pre-OCs were 
then differentiated in the presence of 25ng/ml M-CSF + 25ng/ml RANK-L (MR) or MR 
+10ng/ml TNF (MRT). mRNA expression of CSFR1 was evaluated at 0, 4, 12, and 24h after 
cytokine addition on CD14+ pre-OCs. n=4. 
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Figure S6. TNF does not affect cell apoptosis. CD14+ monocytes were enriched from 
PBMCs and incubated overnight with 25 ng/ml M-CSF to obtain CD14+-derived OC 
precursors (time 0h); these cells were subsequently incubated with 25ng/ml M-CSF ±25ng/ml 
RANK-L (MR) ±TNF at different concentrations (0.1, 1, or 10 ng/ml; T0.1, T1 and T10 
respectively) for 48h and viability quantified using the Vybrant ® FAM Poly Caspases Assay 
Kit (ThermoFisher Scientific) following the manufacturer’s instructions. H2O2 was used as 
positive control. (A) Representative density plots showing gating strategy for calculating 
apoptotic cells (FLICA +) and necrotic cells (PI+) in M-CSF (M), M±RANK-L (MR), 
MR±10ng/ml TNF (MR+T10), and H2O2 samples. (B) Quantification of % of apoptotic cells 
(FLICA +) and necrotic cells (PI+) in n=3 independent experiments. Error bars show 
mean±SD.  
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Figure S7. TNFR2 expression increases during osteoclast differentiation and mediates 
TNF pro-osteoclastogenic effects in pre-fusion OCs. (A-B) CD14+ monocytes were 
enriched from PBMCs and incubated overnight with 25 ng/ml M-CSF to obtain CD14+-
derived OC precursors (time 0h); these cells were subsequently incubated with M-CSF and 
RANK-L (MR) for 72h to differentiate into pre-fusion OCs. (A) Representative half-offset 
histograms show TNFR1 and TNFR2 fluorescence of CD14+-derived OC precursors (0h) and 
after 72h with 25ng/ml RANK-L (iso=isotype control for each of the TNFR antibody). (B) 
Graphs show ΔMFI of TNFR1 and TNFR2 of total single live cells at 0h and 72h of 25ng/ml 
RANK-L. ΔMFI of TNFR1 and TNFR2 was calculated by subtracting the MFI of the TNFR 
to the relative MFI of the isotype control. Data were analysed using Wilcoxon rank test for 
paired data. *P≤0.05. n=6 from 2 different experiments pooled together. (C-D) CD14+-
derived OC precursors were differentiated with 1ng/ml RANK-L (MR) for 72h into pre-
fusion OCs and then 10ng/ml TNF was added onto the culture (MRT) ± antibody blocking 
TNFR1 or TNFR2 (αTNFR1 and αTNFR1) or ± the respective isotype controls (iso1 and 
iso2 respectively).  (C) Representative 20X digital images of TRAP staining at day 10 (D) 
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quantification of numbers of OCs per well. Statistical significance was assessed with 2-way 
ANOVA and Sidak's multiple comparisons test, comparing all data to MRT. Error bars = 
mean±SD of n=3. ****P<0.0001. 
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Figure S8 - Comparison between RA blood and synovial CD1C cells. (A) Comparison of 
global gene expression profiles between RA patient blood and synovium. Each dot is a gene. 
The x and y axis show expression (log10) of each gene in RA patient blood and synovium 
respectively. (B) RANK gene expression in CD1C cells isolated from HC blood, RA blood 
and RA synovial. Data were analysed with one-way ANOVA and Holm-Sidak's multiple 
comparisons test. ****=P<0.0001 and n=3.  
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Age 67.54±9.04 






Table S1. RA patient’s characteristics. CDAI = Clinical Disease Activity Index; SDAI = 
Simplified Disease Activity Index; DAS = Disease Activity Score; ESR = Erythrocyte 




RANK Forward GCTGTAACAAATGTGAACCAGGA 
RANK Reverse GCCTTGCCTGTATCACAAACT 
CFS1R Forward TCCCAGTGATAGAGCCCAGT 
CFS1R Reverse CAGGGTCCAGTGAGGTGATG 
GAPDH Forward  GAAGGACTCATGACCACAGT 
GAPDH Reverse  GTAGAGGCAGGGATGATGTT 





RANK promoter Forward GCTGGCCCCAACATTTTGAA 
RANK promoter Reverse CGTCGAGAATGAACGGGAGG 
CSF1R promoter Forward ACACTGGACACACGTTCCTC 
CSF1R promoter Reverse TCCAAACTCTGTGGTTGCCT 
GAPDH promoter Reverse  TCATCCAAGCGTGTAAGGGT 
GAPDH promoter Forward  ACTGAGATTGGCCCGATGG 
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